| Metric | Value ($ M) |
|---|---|
| Revenue | 53.66 |
| Total Income | 53.66 |
| Expenditure | 54.02 |
| PBT | -1.56 |
| Net Profit | -1.64 |
| OPM | -0.66% |
| NPM | -3.06% |
| EPS | -0.01 |
Cerus Reports Q1 2026 Revenue Up 23% to $59.9 Million
03 May 2026 · 3 May, 6:12 pm
Summary
Cerus Corporation announced a strong start to 2026, with first quarter total revenue increasing by 23% to $59.9 million and product revenue up 24% to $53.7 million. The growth was driven by increasing demand for INTERCEPT Fibrinogen Complex and the global platelet franchise. As a result of this strong performance, the company is raising its full-year product revenue guidance to $227 million - $231 million. Vivek Jayaraman will be appointed as president and chief executive officer, effective July 1, 2026, while William “Obi” Greenman will become executive chairman of the board of directors.
Key Highlights
- 1
Cerus Corporation's first quarter 2026 total revenue reached $59.9 million, a 23% increase compared to the prior year.
- 2
Product revenue for the first quarter of 2026 was $53.7 million, representing a 24% year-over-year growth.
- 3
The company's first quarter U.S. IFC sales totaled $5.7 million, up from $3.0 million in the prior year period.
- 4
First quarter volumes for INTERCEPT Fibrinogen Complex increased by approximately 120% compared to the prior year period.
- 5
The company is raising full-year 2026 product revenue guidance to a range of $227 million to $231 million, reflecting a 10% to 12% year-over-year increase.
- 6
Cash, cash equivalents, and short-term investments totaled $80.4 million at March 31, 2026.
- 7
A new four-year supply agreement was signed with Établissement Français du Sang for the INTERCEPT Blood System.
Management Comments
William “Obi” Greenman
“We delivered a strong start to 2026, with first quarter performance driven by strength across our business, in particular by increasing demand for our INTERCEPT Fibrinogen Complex." “As a result, we are raising our product revenue guidance for the year. Looking ahead, we have a meaningful catalyst path in 2026, spanning anticipated regulatory, clinical, and pipeline milestones, including ongoing INTERCEPT RBC regulatory review in Europe, the Phase 3 RedeS readout in the U.S., and the planned U.S. PMA submission for our new INT200 illumination device.”
Informational and educational content only. Not investment advice.